JPWO2020043762A5 - - Google Patents

Claims (31)

A selenate-containing compound and citric acid, acetic acid, and citric acid, acetic acid, A pharmaceutical composition for intravaginal application, comprising a pharmaceutically acceptable acid selected from malic acid, carbonic acid, sulfuric acid, nitric acid, hydrochloric acid, fruit acids and mixtures thereof. The patient is p16 positive , or p16 positive and Ki-67 positive in at least a region of the internal reproductive organs, until the patient is p16 negative , or p16 negative and Ki-67 negative in said region. 1. The pharmaceutical composition according to 1. A pharmaceutical composition according to claim 1 or 2 , wherein the total selenium content is between 0.01 mg and 1.25 mg per 5 ml of composition. A pharmaceutical composition according to claim 1 or 2, wherein the total selenium content is between 0.025 mg and 1.00 mg per 5 ml of composition. A pharmaceutical composition according to claim 1 or 2, wherein the total selenium content is between 0.05 mg and 0.75 mg per 5 ml of composition. A pharmaceutical composition according to claim 1 or 2, wherein the total selenium content is between 0.10 mg and 0.50 mg per 5 ml of composition. A pharmaceutical composition according to claim 1 or 2, wherein the total selenium content is between 0.15 mg and 0.40 mg per 5 ml of composition. A pharmaceutical composition according to claim 1 or 2, wherein the total selenium content is between 0.20 mg and 0.30 mg per 5 ml of composition. A pharmaceutical composition according to any one of claims 1 to 8 , wherein the total selenium dose is between 0.01 mg and 1.25 mg per application. A pharmaceutical composition according to any one of claims 1 to 8, wherein the total selenium dose is between 0.025 mg and 1.00 mg per application. A pharmaceutical composition according to any one of claims 1 to 8, wherein the total selenium dose is between 0.05 mg and 0.75 mg per application. A pharmaceutical composition according to any one of claims 1 to 8, wherein the total selenium dose is between 0.10 mg and 0.50 mg per application. A pharmaceutical composition according to any one of claims 1 to 8, wherein the total selenium dose is between 0.15 mg and 0.40 mg per application. A pharmaceutical composition according to any one of claims 1 to 8, wherein the total selenium dose is between 0.20 mg and 0.30 mg per application. A pharmaceutical composition according to any one of claims 1 to 14 , wherein the composition is applied at least once a day and optionally said application is discontinued during the patient's menstruation. A pharmaceutical composition according to any one of claims 1 to 14, wherein the composition is applied for at least 30 days and optionally said application is discontinued during the patient's menstruation. A pharmaceutical composition according to any one of claims 1 to 14, wherein the composition is applied for at least 60 days and optionally said application is discontinued during the patient's menstruation. A pharmaceutical composition according to any one of claims 1 to 14, wherein the composition is applied for at least 90 days and optionally said application is discontinued during the patient's menstruation. A pharmaceutical composition according to any one of claims 1 to 18 , wherein said composition is applied once daily, optionally said application is discontinued during the patient's menstruation. A pharmaceutical composition according to any one of claims 1 to 19 , wherein said application is discontinued during the patient's menstruation. A pharmaceutical composition according to any one of claims 1 to 20 , wherein said composition is applied until the internal genital tract infection is no longer detected. A pharmaceutical composition according to any one of claims 1 to 21 , wherein said composition is in the form of a gel, suspension, emulsion, suppository such as a gelatin or gelatin-free capsule, a spray or a powder. thing. The pharmaceutical composition according to any one of claims 1-22, wherein said composition further comprises silicon dioxide. A pharmaceutical composition according to any one of claims 1 to 22, wherein said composition further comprises highly dispersed silicon dioxide. The pharmaceutical composition according to any one of claims 1-24, having a pH of less than 7.0. The pharmaceutical composition according to any one of claims 1-24, having a pH of less than 5.0. The pharmaceutical composition according to any one of claims 1-24, having a pH of 4.0-2.5. The pharmaceutical composition according to any one of claims 1-27, wherein the pharmaceutically acceptable acid is citric acid. The pharmaceutical composition according to any one of claims 1-28, wherein the selenite-containing compound is sodium selenite. A pharmaceutical composition according to any one of claims 1 to 29 , wherein the internal reproductive organ is the patient's vagina or cervix. Pharmaceutical composition according to any one of claims 1 to 30 , wherein the patient does not have cancer and/or chronic viral diseases other than HPV infection and/or the patient is not immunosuppressed.